Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02563925 · ClinicalTrials.gov registry record · NA
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02563925: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02563925 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02563925, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the combination of tremelimumab and durvalumab with brain radiation therapy can help treat this type of breast cancer that has spread to the brain.
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- RADIATION Brain radiotherapy or Stereotactic Radiosurgery
- DRUG HER2 directed therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-09-18 |
| Est. Completion | 2021-07-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02563925
The ClinicalTrials.gov registry entry for NCT02563925 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Durvalumab is the first listed.
NCT02563925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02563925 about?
NCT02563925 is a clinical study titled "Brain Irradiation and Tremelimumab in Metastatic Breast Cancer". The purpose of this study is to see if the combination of tremelimumab and durvalumab with brain radiation therapy can help treat this type of breast cancer that has spread to the brain.
What is the current status of trial NCT02563925?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2015-09-18. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT02563925?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Brain radiotherapy or Stereotactic Radiosurgery (RADIATION), HER2 directed therapy (DRUG).
Who is sponsoring clinical trial NCT02563925?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.